JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2020, 69(3):121-129 | DOI: 10.36290/csf.2020.019

Metal complexes in medicine and pharmacy - the past and the present III

Ladislav Habala*, Jindra Valentová
Katedra chemickej teórie liečiv, Farmaceutická fakulta UK, Bratislava, Slovak Republic

Bioactive metal complexes represent a promising and rapidly evolving area of pharmacotherapy. After the first part of our survey on metallopharmaceuticals dealing with antimicrobial activity of metal complexes and their application in diagnostics and the second part dedicated to anticancer properties of these compounds, this third and last part of the review focuses on several other applications of metals in therapy (mainly on the therapy of rheumatoid arthritis, some mental diseases, diabetes, as well as on chelation therapy). Following a brief account of the historical development of clinical use of the respective category of drugs, their chemical properties, toxicity, clinical applications and mechanism of action are discussed. The aim of this brief survey is to provide basic outline of the area of metallopharmacy, aimed at specialists in pharmacy and chemistry as well as at the general educated public.

Keywords: bioinorganic chemistry; metal complexes; metallopharma-ceuticals; Gold; vanadium; Lithium; chelation therapy
Grants and funding:

Práca bola podporovaná Vedeckou grantovou agentúrou MŠVVaŠ SR a SAV, grant VEGA 1/0346/16.

Received: December 6, 2019; Accepted: January 16, 2020; Published: March 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Habala L, Valentová J. Metal complexes in medicine and pharmacy - the past and the present III. Čes. slov. farm. 2020;69(3):121-129. doi: 10.36290/csf.2020.019.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Raubenheimer H. G., Schmidbaur H. The late start and amazing upswing in gold chemistry. J. Chem. Ed. 2014; 91, 2024-2036. Go to original source...
    2. Faa G., Gerosa C., Fanni D., Lachowicz J. I., Nurchi V. M. Gold - old drug with new potentials. Curr. Med. Chem. 2018; 25, 75-84. Go to original source... Go to PubMed...
    3. Forestier R. L'aurothérapie dans les rhumatismes chroniques. Bulletins et memoires de la Société medicale des hôpitaux de Paris 1929; 44, 323-327.
    4. Forestier R. The treatment of rheumatoid arthritis with gold salts injections. Lancet 1932; 219, 441-444. Go to original source...
    5. Bullock J., Rizvi S. A. A., Saleh A. M., Ahmed S. S., Do D. P., Ansari R. A., Ahmed J. Rheumatoid arthritis: a brief overview of the treatment. Med. Princ. Pract. 2018; 27, 501-507. Go to original source... Go to PubMed...
    6. Naggar M. E., Shehadi I., Abdou H. E., Mohamed A. A. Gilded hope for medicine. Inorganics 2015; 3, 139-154. Go to original source...
    7. Kean W. F., Hart L., Buchanan W. W. Auranofin. Br. J. Rheumatol. 1997; 36, 560-572. Go to original source... Go to PubMed...
    8. Eisler R. Chrysotherapy: a synoptic review. Inflamm. Res. 2003; 52, 487-501. Go to original source... Go to PubMed...
    9. Brown C. L., Whitehouse M. W., Tiekink E. R. T., Bushell G. R. Colloidal metallic gold is not bio-inert. Inflammopharmacology 2008; 16, 133-137. Go to original source... Go to PubMed...
    10. Rovenský J., Rybár I., Mičeková D., Žlnay D., Lukáč J., Poprac P. Farmakoterapeutické postupy pri reumatoidnej artritíde. Via Pract. 2005; 2, 66-74.
    11. Roder C., Thomson M. J. Auranofin: repurposing an old drug for a golden new age. Drugs R. D. 2015; 15, 13-20. Go to original source... Go to PubMed...
    12. Mukherjee B., Patra B., Mahapatra S., Banerjee P., Tiwari A., Chatterjee M. Vanadium - an element of atypical biological significance. Toxicol. Lett. 2004; 150, 135-143. Go to original source... Go to PubMed...
    13. Rehder D. The role of vanadium in biology. Metallomics 2015; 7, 730-742. Go to original source... Go to PubMed...
    14. Rehder D. Vanadium in health issues. ChemTexts 2018; 4, 1-7. Go to original source...
    15. Lyonett B., Martz M., Martin E. Ľ emploi therapeutique des derivés du vanadium. La Presse Médicale 1899; 32, 191-192.
    16. Thompson K. H., Lichter J., LeBel C., Scaife M. C., McNeill J. H., Orvig C. Vanadium treatment of type 2 diabetes: A view to the future. J. Inorg. Biochem. 2009; 103, 554-558. Go to original source... Go to PubMed...
    17. Pessoa J. C., Etcheverry S., Gambino D. Vanadium compounds in medicine. Coord. Chem. Rev. 2015; 301-302, 24-48. Go to original source... Go to PubMed...
    18. Scior T., Guevara-Garcia J. A., Do Q.-T., Bernard P., Laufer S. Why antidiabetic vanadium complexes are not in the pipeline of "Big Pharma" drug research? A critical review. Curr. Med. Chem. 2016; 23, 2874-2891. Go to original source... Go to PubMed...
    19. Levina A., Lay P. A. Metal-based anti-diabetic drugs: advances and challenges. Dalton Trans. 2011; 40, 11675-11686. Go to original source... Go to PubMed...
    20. Wang Z. Q., Cefalu W. T. Current concepts about chromium supplementation in type 2 diabetes and insulin resistance. Curr. Diabetes Rep. 2010; 10, 145-151. Go to original source... Go to PubMed...
    21. Bauer M., Gitlin M. The Essential Guide to Lithium Treatment. Springer International Publishing Switzerland 2016. Go to original source...
    22. Garrod A. B. The Nature and Treatment of Gout and Rheumatic Gout. London: Walton and Maberly 1859.
    23. Lange C. Om Periodisk e Depressionstilstande og deres Patogenese. Copenhagen: Jacob Lunds Forlag 1886.
    24. Cade J. F. Lithium salts in the treatment of psychotic excitement. Med. J. Aust. 1949; 2, 349-351. Go to original source...
    25. Baastrup P. C., Schou M. Lithium as a prophylactic agent: its effect against recurrent depression and manic-depressive psychosis. Arch. Gen. Psychiatry 1967; 16, 162-172. Go to original source... Go to PubMed...
    26. Herman E., Praško J., Hovorka J. Místo stabilizátorů nálady v léčbě bipolární poruchy. Psychiat. pro Praxi 2006; 4, 161-164.
    27. Makara-Studzińska M., Koślak A., Morylowska-Topolska J., Urbańska A. Lithium therapy - the effectiveness of the medicine, side symptoms, complications and their influence on the quality of the life in affective diseases. J. Elementol. 2010; 15, 393-403.
    28. Virčík Ľ., Rusínová E. Vedľajšie účinky liečby lítiom, ich mechanizmy a zvládnutie. Čes. a slov. Psychiat. 2005; 101, 36-39.
    29. Birch N. J. Inorganic pharmacology of lithium. Chem. Rev. 1999; 99, 2659-2682. Go to original source... Go to PubMed...
    30. Kiełczykowska M., Musik I. Lithium and the application of its compounds in different fields of medicine. J. Elementol. 2014; 19, 1167-1178. Go to original source...
    31. Crichton R., Ward R. J., Hider R. C. (ed.) Metal Chelation in Medicine. Cambridge: Royal Society of Chemistry 2017. Go to original source...
    32. Baran E. J. Chelation therapies: A chemical and biochemical perspective. Curr. Med. Chem. 2010; 17, 3658-3672. Go to original source... Go to PubMed...
    33. Aaseth J., Skaug M. A., Cao Y., Andersen O. Chelation in metal intoxication - principles and paradigms. J. Trace Elem. Med. Biol. 2015; 31, 260-266. Go to original source... Go to PubMed...
    34. Kim J.-J., Kim Y.-S., Kumar V. Heavy metal toxicity: an update of chelating therapeutic strategies. J. Trace Elem. Med. Biol. 2019; 54, 226-231. Go to original source... Go to PubMed...
    35. Scott L. E., Orvig C. Medicinal inorganic chemistry approaches to passivation and removal of aberant metal ions in disease. Chem. Rev. 2009; 109, 4885-4910. Go to original source... Go to PubMed...
    36. Litwin T., Dusek P., Skowrońska M., Członkowska A. Treatment of Wilson's disease - an update. Expert Opin. Orphan Drugs 2019; 7, 287-294. Go to original source...
    37. Nurchi V. M., Crisponi G., Lachowicz J. I., Medici S., Peana M., Zoroddu M. A. Chemical features of in use and in progress chelators for iron overload. J. Trace Elem. Med. Biol. 2016; 38, 10-18. Go to original source... Go to PubMed...
    38. Yu Y., Gutierrez E., Kovacevic Z., Saletta F., Obeidy P., Suryo Rahmanto Y., Richardson D. R. Iron chelators for the treatment of cancer. Curr. Med. Chem. 2012; 19, 2689-2702. Go to original source... Go to PubMed...
    39. Crisponi G., Nurchi V. M., Lachowicz J. I., Crespo-Alonso M., Zoroddu M. A., Peana M. Kill or cure: misuse of chelation therapy for human diseases. Coord. Chem. Rev. 2015; 284, 278-285. Go to original source...
    40. Moreno C. R., Navas-Acien A., Escolar E., Nathan D. M., Newman J., Schmedtje J. F., Diaz D., Lamas G. A., Fonseca V. Potential role of metal chelation to prevent the cardiovascular complications of diabetes. J. Clin. Endocrinol. Metab. 2019; 104, 2931-2941. Go to original source... Go to PubMed...
    41. Kilpin K. J., Dyson P. J. Enzyme inhibition by metal complexes: concepts, strategies and applications. Chem. Sci. 2013; 4, 1410-1419. Go to original source...
    42. Krajnc A., Lang P. A., Panduwawala T. D., Brem J., Schofield C. J. Will morphing boron-based inhibitors beat the β-lactamases? Curr. Opin. Chem. Biol. 2019; 50, 101-110. Go to original source... Go to PubMed...
    43. Tfouni E., Truzzi D. R., Tavares A., Gomes A. J., Figueiredo L. E., Franco D. W. Biological activity of ruthenium nitrosyl complexes. Nitric Oxide 2012; 26, 38-53. Go to original source... Go to PubMed...
    44. Friederich J. A., Butterworth J. F. Sodium nitroprusside: twenty years and counting. Anesth. Analg. 1995; 81, 152-162. Go to original source...
    45. Riley D. P. Functional mimics of superoxide dismutase enzymes as therapeutic agents. Chem. Rev. 1999; 99, 2573-2588. Go to original source... Go to PubMed...
    46. Salvemini D., Muscoli C., Riley D. P., Cuzzocrea S. Superoxide dismutase mimetics. Pulm. Pharmacol. Ther. 2002; 15, 439-447. Go to original source... Go to PubMed...
    47. Hasenknopf B. Polyoxometalates: introduction to a class of inorganic compounds and their biomedical applications. Front. Biosci. 2005; 10, 275-287. Go to original source... Go to PubMed...
    48. Rhule J. T., Hill C. L., Judd D. A., Schinazi R. F. Polyoxometalates in medicine. Chem. Rev. 1998; 98, 327-358. Go to original source... Go to PubMed...
    49. van Rompuy, L. S., Parac-Vogt, T. N. Interactions between polyoxometalates and biological systems: from drug design to artificial enzymes. Curr. Opin. Biotech. 2019; 58, 92-99. Go to original source... Go to PubMed...
    50. Poole K. At the nexus of antibiotics and metals: the impact of Cu and Zn on antibiotic activity and resistance. Trends Microbiol. 2017; 25, 820-832. Go to original source... Go to PubMed...
    51. Yazdankhah S., Rudi K., Bernhoft A. Zinc and copper in animal feed - development of resistance and co-resistance in antimicrobial agents in bacteria of animal origin. Microb. Ecol. Health Dis. 2014; 25, 25862. Go to original source... Go to PubMed...
    52. Eisner H., Porzecanski B. Inactivation of penicillin by zinc salts. Science 1946; 103, 629-630. Go to original source... Go to PubMed...
    53. Elkhatib W., Noreddin A. In vitro antibiofilm efficacies of different antibiotic combinations with zinc sulfate against Pseudomonas aeruginosa recovered from hospitalized patients with urinary tract infection. Antibiotics (Basel) 2014; 3, 64-84. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.